Xiayu Rao
Overview
Explore the profile of Xiayu Rao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1693
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Amit M, Takahashi H, Dragomir M, Lindemann A, Gleber-Netto F, Pickering C, et al.
Nature
. 2020 Feb;
578(7795):449-454.
PMID: 32051587
The solid tumour microenvironment includes nerve fibres that arise from the peripheral nervous system. Recent work indicates that newly formed adrenergic nerve fibres promote tumour growth, but the origin of...
12.
Lindemann A, Patel A, Silver N, Tang L, Liu Z, Wang L, et al.
Clin Cancer Res
. 2019 Jul;
25(18):5650-5662.
PMID: 31308060
Purpose: 53 mutations are highly prevalent in head and neck squamous cell carcinoma (HNSCC) and associated with increased resistance to conventional treatment primarily consisting of chemotherapy and radiation. Restoration of...
13.
Tailor T, Rao X, Campa M, Wang J, Gregory S, Patz Jr E
Front Oncol
. 2019 May;
9:317.
PMID: 31069172
Indeterminate pulmonary lesions (IPL) detected by CT pose a significant clinical challenge, frequently necessitating long-term surveillance or biopsy for diagnosis. In this pilot investigation, we performed whole exome sequencing (WES)...
14.
Singh R, Peng S, Viswanath P, Sambandam V, Shen L, Rao X, et al.
EMBO Mol Med
. 2019 May;
11(5).
PMID: 31040125
To address the need for improved systemic therapy for non-small-cell lung cancer (NSCLC), we previously demonstrated that mesenchymal NSCLC was sensitive to polo-like kinase (Plk1) inhibitors, but the mechanisms of...
15.
Kettner N, Vijayaraghavan S, Guray Durak M, Bui T, Kohansal M, Ha M, et al.
Clin Cancer Res
. 2019 Mar;
25(13):3996-4013.
PMID: 30867218
Purpose: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are currently used in combination with endocrine therapy to treat advanced hormone receptor-positive, HER2-negative breast cancer. Although this treatment doubles time to progression compared...
16.
Sambandam V, Frederick M, Shen L, Tong P, Rao X, Peng S, et al.
Clin Cancer Res
. 2019 Feb;
25(11):3329-3340.
PMID: 30770351
Purpose: Head and neck squamous cell carcinoma (HNSCC) is driven largely by the loss of tumor suppressor genes, including , but lacks a biomarker-driven targeted therapy. Although the PI3K/mTOR pathway...
17.
Gleber-Netto F, Rao X, Guo T, Xi Y, Gao M, Shen L, et al.
JCI Insight
. 2019 Jan;
4(1).
PMID: 30626753
Incidence of HPV+ oropharyngeal squamous cell carcinoma (OPSCC) has been increasing dramatically. Although long-term survival rates for these patients are high, they often suffer from permanent radiotherapy-related morbidity. This has...
18.
Sandulache V, Michikawa C, Kataria P, Gleber-Netto F, Bell D, Trivedi S, et al.
Clin Cancer Res
. 2018 Jan;
24(7):1727-1733.
PMID: 29330202
Development of extranodal extension (ENE) has been associated with poor survival in patients with oral cavity squamous cell carcinoma (OSCC). Here, we sought to confirm the role of ENE as...
19.
Gadhikar M, Zhang J, Shen L, Rao X, Wang J, Zhao M, et al.
Cancer Res
. 2017 Dec;
78(3):781-797.
PMID: 29229598
Checkpoint kinase inhibitors (CHKi) exhibit striking single-agent activity in certain tumors, but the mechanisms accounting for hypersensitivity are poorly understood. We screened a panel of 49 established human head and...
20.
Kalu N, Mazumdar T, Peng S, Shen L, Sambandam V, Rao X, et al.
Oncotarget
. 2017 Nov;
8(49):86369-86383.
PMID: 29156801
Human cancer cell lines are the most frequently used preclinical models in the study of cancer biology and the development of therapeutics. Although anatomically diverse, human papillomavirus (HPV)-driven cancers have...